TVARDI THERAPEUTICS, INC. Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price
TVARDI THERAPEUTICS, INC. (TVRD) reported Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price of $176.43 per share for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-11.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures and Expirations in Period, Weighted Average Exercise Price
us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice · last filed 2025-03-11
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for the quarter ending 2024-03-31 was $13.36.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2024 was $176.43, a 1096.95% increase from fiscal 2023.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2023 was $14.74, a 8.39% decline from fiscal 2022.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2022 was $16.09, a 35.46% decline from fiscal 2021.
- TVARDI THERAPEUTICS, INC. share-based compensation arrangements by share-based payment award, options, expirations in period, weighted average exercise price for fiscal 2021 was $24.93, a 77.31% increase from fiscal 2020.
| Period end | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 3 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 6 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 9 month | Share-based Compensation Arrangements by Share-based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price 12 month |
|---|---|---|---|---|
| 2024-12-31 | $176.43 10-K · filed 2025-03-11 | |||
| 2024-09-30 | $14.92 10-Q · filed 2024-11-14 | |||
| 2024-06-30 | $14.15 10-Q · filed 2024-08-14 | |||
| 2024-03-31 | $13.36 10-Q · filed 2024-05-13 | |||
| 2023-12-31 | $14.74 10-K · filed 2024-03-06 | |||
| 2023-09-30 | $14.48 10-Q · filed 2023-11-13 | |||
| 2023-06-30 | $14.35 10-Q · filed 2023-08-07 | |||
| 2022-12-31 | $16.09 10-K · filed 2023-03-06 | |||
| 2021-12-31 | $24.93 10-K · filed 2022-03-01 | |||
| 2020-12-31 | $14.06 10-K · filed 2021-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Vyome Holdings, Inc (HIND) | United States | $0.014B | -1.38 |
| BullFrog AI Holdings, Inc. (BFRG) | United States | $0.014B | |
| ACTUATE THERAPEUTICS, INC. (ACTU) | United States | $0.015B | |
| Anebulo Pharmaceuticals, Inc. (ANEB) | United States | $0.015B | |
| LISATA THERAPEUTICS, INC. (LSTA) | United States | $0.014B | -2.13 |
| Lantern Pharma Inc. (LTRN) | United States | $0.015B | -2.87 |
| Vistagen Therapeutics, Inc. (VTGN) | United States | $0.013B | -0.14 |
| MUSTANG BIO, INC. (MBIO) | United States | $0.013B | |
| Citius Pharmaceuticals, Inc. (CTXR) | United States | $0.016B | -133.06 |
| AEON Biopharma, Inc. (AEON) | United States | $0.013B | -0.36 |